Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2011

View Archived Issues

New carbapenem antibiotics described

Irosustat demonstrates pharmacodynamic proof of concept

New DNA vaccine is efficacious in monkey model of tuberculosis

Gantenerumab reduces amyloid levels in brain

Scientists in U.K. identify microRNA biomarker in COPD

Phase I/II data disclosed on trabedersen in melanoma, pancreatic and colorectal carcinoma

Intellikine advances first-in-human trial of INK-1117

Ironwood Pharmaceuticals prepares new GCS activators

Isis Pharmaceuticals selects second development candidate in GlaxoSmithKline collaboration

Dainippon Sumitomo Pharma discloses novel agents for sepsis

ISCO reports promising preclinical results with hpSC-derived neuronal cells

New deuterated dimethylcurcumin derivatives claimed by Concert Pharmaceuticals

Scientists at Gilead Sciences patent new SYK inhibitors

Novel histamine receptor antagonists presented by Kalypsys

Medicago completes first stage of noninfluenza VLP vaccine collaboration agreement

Michael J. Fox Foundation funds clinical study of Parkinson's disease vaccine

ISTA provides update on development of bromfenac ophthalmic solutions

Topline data reported from Pozen's phase III PA-32540 study

FDA grants pre-IND meeting to Advaxis for ADXS-HER2

DSMB recommends continuing Cyclacel's SEAMLESS trial

Micromet outlines registration strategy for blinatumomab

Kissei Pharmaceutical to pay MediciNova for further development of MN-221

Baxter International starts phase III trial of recombinant von Willebrand factor

FDA committee recommends approval of Zilver PTX paclitaxel-eluting stent

Telik commences phase IIb trial of Telintra

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...